Cardio Diagnostics Ownership

CDIO Stock  USD 0.43  0.02  4.44%   
Cardio Diagnostics holds a total of 52.15 Million outstanding shares. Cardio Diagnostics Holdings shows 7.68 percent of its outstanding shares held by insiders and 4.9 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Cardio Diagnostics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cardio Diagnostics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardio Diagnostics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Cardio Stock Ownership Analysis

The book value of the company was currently reported as 0.12. The company recorded a loss per share of 0.31. Cardio Diagnostics had not issued any dividends in recent years. Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of cardiovascular disease. Cardio Diagnostics Inc. was founded in 2017 and is based in Chicago, Illinois. Cardio Diagnostics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Cardio Diagnostics Holdings please contact Meeshanthini Dogan at 302 281 2147 or go to https://cardiodiagnosticsinc.com.
Besides selling stocks to institutional investors, Cardio Diagnostics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cardio Diagnostics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cardio Diagnostics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Cardio Diagnostics Quarterly Liabilities And Stockholders Equity

4.48 Million

About 8.0% of Cardio Diagnostics Holdings are currently held by insiders. Unlike Cardio Diagnostics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cardio Diagnostics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cardio Diagnostics' insider trades

Cardio Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cardio Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardio Diagnostics Holdings backward and forwards among themselves. Cardio Diagnostics' institutional investor refers to the entity that pools money to purchase Cardio Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Scientech Research Llc2024-12-31
34.5 K
Xtx Topco Ltd2024-12-31
22.9 K
Lpl Financial Corp2024-12-31
15.2 K
Endowment Wealth Management, Inc.2024-12-31
14.3 K
Tower Research Capital Llc2024-12-31
7.5 K
Advisor Group Holdings, Inc.2024-12-31
4.3 K
Wolverine Asset Management Llc2024-12-31
3.8 K
Cwm, Llc Duplicate2024-12-31
3.5 K
Morgan Stanley - Brokerage Accounts2024-12-31
K
Blackrock Inc2024-12-31
1.1 M
Geode Capital Management, Llc2024-12-31
364.4 K
Note, although Cardio Diagnostics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cardio Diagnostics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardio Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardio Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cardio Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Lau Stanley K. over a week ago
Acquisition by Lau Stanley K. of 21008 shares of Cardio Diagnostics at 1.19 subject to Rule 16b-3
 
Lau Stanley K. over a month ago
Acquisition by Lau Stanley K. of 917 shares of Cardio Diagnostics at 2.18 subject to Rule 16b-3
 
Meeshanthini Dogan over two months ago
Acquisition by Meeshanthini Dogan of 272250 shares of Cardio Diagnostics at 1.26 subject to Rule 16b-3
 
Hosseinion Warren over two months ago
Acquisition by Hosseinion Warren of 123750 shares of Cardio Diagnostics at 1.26 subject to Rule 16b-3
 
Intrater James over two months ago
Acquisition by Intrater James of 4544 shares of Cardio Diagnostics at 0.92 subject to Rule 16b-3
 
Burton Paul Frederick over three months ago
Acquisition by Burton Paul Frederick of 18686 shares of Cardio Diagnostics at 0.22 subject to Rule 16b-3
 
Lau Stanley K. over six months ago
Acquisition by Lau Stanley K. of tradable shares of Cardio Diagnostics subject to Rule 16b-3
 
Philibert Robert over six months ago
Acquisition by Philibert Robert of 7460 shares of Cardio Diagnostics at 0.2848 subject to Rule 16b-3
 
Meeshanthini Dogan over six months ago
Acquisition by Meeshanthini Dogan of 68965 shares of Cardio Diagnostics at 0.29 subject to Rule 16b-3
 
Timur Dogan over six months ago
Acquisition by Timur Dogan of 156750 shares of Cardio Diagnostics at 1.26 subject to Rule 16b-3
 
Philibert Robert over six months ago
Acquisition by Philibert Robert of 142876 shares of Cardio Diagnostics at 2.11 subject to Rule 16b-3
 
Levy Oded over six months ago
Acquisition by Levy Oded of 7575 shares of Cardio Diagnostics at 0.55 subject to Rule 16b-3

Pair Trading with Cardio Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cardio Stock

  0.69CDIOW Cardio DiagnosticsPairCorr
  0.75ELVN Enliven Therapeutics Downward RallyPairCorr

Moving against Cardio Stock

  0.81GE GE AerospacePairCorr
  0.77WM Waste ManagementPairCorr
  0.73PLX Protalix BiotherapeuticsPairCorr
  0.6LUCD Lucid DiagnosticsPairCorr
  0.42MLSS Milestone Scientific Earnings Call TomorrowPairCorr
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cardio Diagnostics is a strong investment it is important to analyze Cardio Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardio Diagnostics' future performance. For an informed investment choice regarding Cardio Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardio Diagnostics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardio Diagnostics. If investors know Cardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.31)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.34)
Return On Assets
(1.00)
Return On Equity
(2.76)
The market value of Cardio Diagnostics is measured differently than its book value, which is the value of Cardio that is recorded on the company's balance sheet. Investors also form their own opinion of Cardio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Cardio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardio Diagnostics' market value can be influenced by many factors that don't directly affect Cardio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardio Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.